Cellectis Posts Q2 2026 Results, Highlights Progress Across Allogenic CAR-T Pipeline

Cellectis (CLLS) reported Q2 2026 cash, cash equivalents and fixed-term deposits of $169M as of June 30, 2026, versus $145M in Q2 2025, citing runway into Q4 2027. At EHA 2026, lasme-cel in BALLI-01 moved to pivotal Phase 2 after FDA RMAT (June 2026), with ORR 67% and CR 56% in Phase 1. Eti-cel in NATHALI-01 showed ORR 46% and CR 31%.

Original reporting
Published Aug 7, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CLLS
Bullish
medium confidence
Mentioned
$CLLS
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CLLSBullishMed
01

Why it matters

The combination of stronger liquidity (cash into Q4 2027) and a regulatory milestone (RMAT designation) for lasme-cel, alongside reported response rates, can shift expectations for trial progression and future financing needs.

02

Market read

Traders may reprice Cellectis based on RMAT-linked pivotal progression for lasme-cel and the stated interim Phase 2 analysis window in Q4 2026, supported by improved cash runway.

03

What to watch

Cash runway is extended, but the article does not quantify burn rate, dilution risk, or manufacturing/commercial readiness, which can cap upside despite RMAT progress.

Relevance 7/10Novelty 6/10Timing: today, pre-market/early session coverage of Q2 results and EHA pipeline updates

Background

Cellectis is a clinical-stage biotech focused on gene-edited allogeneic CAR-T therapies, with updates presented at the EHA 2026 Annual Congress.

Company-level read

Ticker impact

$CLLSBullishMedium confidence
Context

Cellectis reported Q2 2026 cash of $169M and advanced lasme-cel to pivotal Phase 2 after FDA RMAT designation in June 2026.

Expected impact

Moderately positive bias, with volatility likely around Q4 2026 interim Phase 2 expectations.

Evidence & confidence

The article adds specific, decision-relevant clinical/regulatory milestones (RMAT in June 2026, pivotal Phase 2, interim analysis expected Q4 2026) plus liquidity runway into Q4 2027, which can support valuation and trading positioning.

Market effects

Supports sentiment for allogeneic CAR-T development, especially CD22-positive B-ALL programs with RMAT-linked momentum.

Limited direct regional impact; EHA congress context may influence European biotech sentiment.

Moderate global read-through for gene-edited cell therapy investors tracking RMAT and pivotal Phase 2 transitions.

Counterpoint

Efficacy metrics are encouraging but still early-stage for pivotal Phase 2; interim Phase 2 timing in Q4 2026 may be too far to re-rate immediately.

Key entities

  • Cellectis

    Reported Q2 2026 liquidity and provided clinical pipeline updates for lasme-cel and eti-cel at EHA 2026.

  • Lasme-cel

    BALLI-01 relapsed/refractory B-ALL program moved into pivotal Phase 2 after FDA RMAT designation in June 2026.

  • Eti-cel

    NATHALI-01 relapsed/refractory non-Hodgkin lymphoma program remains in Phase 1 with full dataset expected in Q4 2026.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.